Former Louisiana Attorney General Alerts Kyverna Therapeutics Investors About Class Action Lawsuit Opportunities

Kyverna Therapeutics Class Action Alert

In a significant development for investors, Kahn Swick & Foti, LLC (KSF), led by former Louisiana Attorney General Charles C. Foti, Jr., has issued an alert regarding potential securities class action lawsuits against Kyverna Therapeutics, Inc. (NasdaqGS: KYTX). This notice is particularly critical for investors who have incurred losses exceeding $100,000 and purchased shares tied to the company’s February 2024 initial public offering (IPO).

Key Dates and Actions

Investors have until February 7, 2025, to file lead plaintiff applications. If you fall into this category, you can reach out to KSF's Managing Partner, Lewis Kahn, toll-free at 1-877-515-1850 or via email at email protected] Further insights can be found on their dedicated [website.

Nature of the Lawsuit

The lawsuit under discussion involves allegations against Kyverna and several executives for failing to provide necessary disclosures in their IPO Registration Statement and Prospectus, violating federal securities laws.

Key points raised in the complaint indicate that while the Offering Documents portrayed positive performance of the lead product candidate, KYV-101, they did not disclose unfavorable data from clinical trials, known to Kyverna at the time of the IPO. This omission has raised concerns as investors only became aware of the discrepancy following the IPO launch, leading to a sharp decline in share prices and significant financial losses for shareholders.

The case is officially referenced as Rondini v. Kyverna Therapeutics, Inc. et al., No. 24-cv-08869. The ongoing litigation is being managed at the United States District Court for the Northern District of California.

Background on Kahn Swick & Foti, LLC

KSF is considered a leading law firm in the field of securities litigation and has represented a wide range of clients, including institutional investors, hedge funds, and retail investors. With offices in multiple states across the nation, KSF is committed to recovering losses incurred due to corporate fraud or misconduct in publicly traded companies. Their experience and focus on investor rights make them a trusted ally for those affected in this situation.

If you purchased Kyverna shares during the specified timeframe, it is essential to act swiftly to protect your legal rights and explore avenues for recovery. With proper legal advice and action, you may have a chance to reclaim your losses.

For more information about KSF and their services, you can visit their website at www.ksfcounsel.com.

As the February 7 deadline approaches, affected investors are encouraged to explore their options and act promptly to ensure their voices are heard in this crucial lawsuit against Kyverna Therapeutics.